Kornimate/medical-research-clean huggingface dataset:
cerebellar stimulation and cognitive control

Conditions: Schizophrenia; Autism Spectrum Disorder; Bipolar Disorder; Depression; Parkinson Disease

Summary: the purpose of this study is to examine whether cerebellar stimulation can be used to improve cognitive deficits and mood in patients with schizophrenia, autism, bipolar disorder, parkinson's disease, and major depression.

our recent work found that patients with parkinson's disease and schizophrenia have impaired frontal eeg rhythms in the theta and delta range (1-8 hz).we have been using transcranial direct current stimulation to recover these rhythms as patients perform elementary cognitive tasks. we found that although we are able to modulate cerebellar and frontal activity with tdcs, this effect is minimal as the depth of the current is not great enough to modulate all cerebellar activity. here we use transcranial magnetic stimulation (tms) to modulate neural activity in the frontal cortex and recover cognitive function in patients with autism, schizophrenia, bipolar disorder and parkinson's disease. the purpose of the study is to explore cerebellar stimulation as a potential new treatment to restore frontal activity and cognitive function in autism, schizophrenia, bipolar disorder and parkinson's disease.subjects will be brought in for 5 to 6 separate visits, with cerebellar or sham tms stimulation twice per day for 5 days, as well as 3 follow-up visits.during these visits the patient will have cognitive, disease-specific and emotional testing, including eeg testing and mri imaging. for those participants that received sham stimulation we will again use eeg to record how single pulses of magnetic or electrical stimulation influences other regions of the cerebellum and downstream brain regions. these data will provide insight into how the cerebellum may influence downstream brain regions and play a role in cognitive and motor performance. all data will be analyzed offline to determine if performance on the interval timing task and/or frontal brain rhythms change following transcranial magnetic stimulation as compared to the pre-stimulation blocks of trials. additionally, we will analyze changes in their cognitive function, symptom ratings, functional and structural mri, and mood following stimulation. controls will receive both active and sham treatment for comparison.

Eligibility criteria:
inclusion criteria: * a clinical diagnosis consistent with enrollment exclusion criteria: * history of recurrent seizures or epilepsy * any other neurological or psychiatric diagnosis outside the diagnosis for which the participant is enrolled. * active substance use disorder in the past 6 months other than tobacco use disorder. * inability to consent for study. * pacemaker * coronary stent * defibrillator * neurostimulation * claustrophobia * uncontrolled high blood pressure * atrial fibrillation * significant heart disease * hemodynamic instability * kidney disease * pregnant, trying to become pregnant, or breast feeding

Keywords: cerebellum
dexmedetomidine in spinal anesthesia

Conditions: Blood Pressure; Anxiety

Summary: patients were randomized into two groups, a group and b group. a group and b group patients are injected intravenous dexmedetomidine after intrathecal injection (it) of heavy bupivacaine and injected intravenous dexmedetomidine before it of heavy bupivacaine, respectively. the investigators will compare of hemodynamics and patient's comfortability between two groups.

a and b group patients will intravenous inject dexmedetomidine 1mcg/kg for 10 minute loading infusion and 0.2mcg/kg/hr for continuous infusion. a group receive intravenous dexmedetomidine after procedure, and b group receive intravenous dexmedetomidine before procedure. both group patients will hydrate 6 ml/kg crystalloid solution and will evaluated patient's anxiety and comfortability perioperative period. vital signs will record 5 minutes interval at operating room and post-anesthetic care units.

Eligibility criteria:
inclusion criteria: * 20 - 60 aged patients * orthopedic operation undergoing spinal anesthesia exclusion criteria: * more than american society of anesthesiologists classification 3 * hypertension * diabetes mellitus * heart disease (bradycardia, atrioventricular block)

Keywords: dexmedetomidine spinal anesthesia
a study of fluzoparib given in combination with apatinib and paclitaxel in gastric cancer patients

Conditions: Recurrent and Metastatic Gastric Cancer

Summary: fluzoparib is an oral potent, selective parp-1 and parp-2 inhibitor; apatinib is an oral selective vegfr inhibitor. this open-label, dose finding phase i trial studies the tolerability and the best dose of fluzoparib in combination with apatinib and paclitaxel and to see how well this three drugs work together in the treatment of patients with recurrent and metastatic gastric cancer who progress following first-line therapy. the safety and efficacy of fluzoparib in combination with apatinib and paclitaxel will be explored.


Eligibility criteria:
inclusion criteria: * ecog performance status of 0 to 1. * life expectancy of more than 12 weeks. * histologically or cytologically confirmed gastric adenocarcinoma( adenocarcinoma of the gastroesophageal junction included). * recurrent or metastatic gastric cancer that has progressed following first line-therapy. * at least one lesion (measurable and/or non-measurable) that can be accurately assessed by imaging (ct/mri) at baseline * subjects who have overall good overall general condition. * signed informed consent. exclusion criteria: * subjects who received any previous treatment with any parp inhibitors. * subjects who received any previous treatment with any taxanes. * more than one prior chemotherapy regimen for the treatment of gastric cancer in the metastatic or recurrent setting. * less than 4 weeks from the last clinical trial. * less than 2 weeks from the last radiotherapy, chemotherapy, surgery, hormone treatment and target therapy. * unstable hypertension. * subjects that are unable to swallow, or dysfunction of gastrointestinal absorption. * subjects with brain metastases. * subjects with uncontrolled hypokalemia and hypomagnesemia before study entry. * subjects with a known hypersensitivity to fluzoparib, apatinib, paclitaxel or any of the excipients of the product. * ongoing infection (determined by investigator). * history of immunodeficiency, including hiv-positive, suffering from other acquired, congenital immunodeficiency disease, or history of organ transplantation. * subjects who can not interrupt the using of the drugs that may cause qt prolongation during study. * pregnant or breast-feeding women.

Keywords: parp inhibitor vegfr inhibitor combination therapy gastric cancer
biotinidase test in optic-neuropathy

Conditions: Biotin Deficiency; Optic Neuropathy

Summary: biotinidase is an enzyme that recycles biotin, a water-soluble vitamin essential as a coenzyme for four carboxylases that are involved in gluconeogenesis, fatty acid synthesis, and in the catabolism of several branch-chain amino acids. biotinidase deficiency (bd) is an autosomal recessively inherited disorder. patients with profound bd (\<10% of mean normal serum biotinidase activity) presents, usually during early childhood, with neurological (seizures, hypotonia, ataxia, developmental delay, vision problems, and/or hearing loss) and non-neurological findings (metabolic acidosis, respiratory difficulties, alopecia and/or skin rash) that may progress to coma or death if untreated. three cases of adult-onset biotinidase deficiency with reversible optic neuropathy have recently been described in france, where there is no neonatal screening of bp. once treated with biotin, patients' vision was fully restored. this study aims to assess the prevalence of bp among a population of patients with idiopathic optic neuropathy, and to assess the efficacy of biotin supplementation on visual impairment in these patients.


Eligibility criteria:
inclusion criteria: * patient with bilateral optic neuropathy * symptoms beginning before 50 years old * diagnosed for more than 1 months * etiology unknown exclusion criteria: * none
second-generation sequencing guides the treatment of severe pneumonia

Conditions: Pneumonia; Metagenomic Next Generation Sequencing

Summary: investigators plan to conduct the participants level, 1:1 randomized trial at the central icu and respiratory icu of xiangya hospital in changsha, china, from january 1, 2018 to december 31, 2019. participants with initial diagnosis of severe pneumonia will be first treated with empiric therapy, after 48-72 hours, the participants's condition will be evaluated, and participants who will have been initially cured and died should be excluded.the participants who will have failed the initial treatment will be then randomly divided into two groups: the ngs group and the conventional treatment group. bronchoalveolar lavage fluid will be taken by bedside bronchoscopy when the participants underwent nasal high-flow oxygen therapy, non-invasive ventilation, and invasive ventilation,or venous blood will be taken for examination. participants in the ngs group will be tested for both ngs and conventional pathogens, however, the routine group will be only routinely tested. according to the pathogen results, participants with non-severe pneumonia will be excluded, and medication should be adjusted under the joint guidance of infectious and respiratory specialists. then investigators will compare the first outcome: 28-day mortality, and secondary outcome: icu hospitalization time, mechanical ventilation time, hospitalization costs, antibiotic use costs, sofa scores, curb-65 scores, apache scores, and other clinical indicators.


Eligibility criteria:
inclusion criteria: * patients diagnosed with severe pneumonia between the ages of 18 and 85 years; the diagnosis of severe pneumonia is based on idsa / ats exclusion criteria: * \< 18 years old, received antibiotic treatment within 14 days before admission, suffering from severe immunosuppression, multi-drug resistance, refractory tuberculosis, end-stage renal disease or liver disease (uremia, advanced liver cancer), pregnancy. besides, we need to rule out patients who have been improved, died, and abandoned during the initial treatment。
small bowel obstruction in virgin abdomen

Conditions: Small Bowel Obstruction Adhesion

Summary: a retrospective study conductet at estonia's two regional hospitals. the data of patients hospitalised for sbo (small bowel obstruction) between 2015-2019 is retrospectively analysed. all other patients are excluded- except for previously unoperated ones (virgin abdomen). study group analyses whether patients were operated on or was conservative management initiated. it will be studied, if any further medical studies have been done within 2 years of hospitalisation.

background: the surgical dogma of mandatory operative management of small bowel obstruction (sbo) in patients without prior abdominal operations was re-evaluated by the world society of emergency surgery (wses) in 2021. a few publications exist on this topic, with a modest number of patients included. the purpose of this study was to analyze the causes and management of small bowel obstruction (sbo) in patients without prior abdominal surgeries. methods: study group retrospectively examined the data of patients hospitalized with sbo from 2015 to 2019. patients without previous abdominal surgeries-virgin abdomen (va) were included. eligible patients' data was evaluated. it was noted whether surgery was performed or conservative management was initiated. in the latter case, information about radiological or endoscopic studies, hospitalizations, or surgeries performed within 2 years after the primary hospitalization was extracted

Eligibility criteria:
inclusion criteria: patients diagnosed with sbo have not been operated previously exclusion criteria: age less than 18 years history of previous operatsions large bowel obstruction dynamic ileus -

Keywords: virgin abdomen sbo
safety and efficacy of anti-bcma/fcrl5 car-t cell therapy in treating relapsed and refractory multiple myeloma (r/r mm)

Conditions: Multiple Myeloma

Summary: this is an open label, single-arm, phase 2 study to evaluate the efficacy and safety of anti-bcma/fcrl5 car-t in subjects with relapsed and refractory multiple myeloma. a leukapheresis procedure will be performed to manufacture. anti-bcmafcrl5 chimeric antigen receptor (car) modified t cells. prior to anti-bcma/fcrl5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide.

this open label, single-arm, phase 2 study aims to evaluate the efficacy and safety of anti-bcma/fcrl5 car-t in subjects with relapsed and refractory multiple myeloma. a leukapheresis procedure will be performed to manufacture. anti-fcrl5 chimeric antigen receptor (car) modified t cells. prior to anti-bcma/fcrl5 infusion subjects will receive lymphodepleting therapy with fludarabine and cyclophosphamide. after infusion, the investigators will observe the characteristics of dose limited toxicity (dlt), and determine the maximum tolerable agent mtd and rp2d were confirmed. to provide basis for the dosage and treatment plan of cell products in follow-up clinical trials.

Eligibility criteria:
inclusion criteria: age is 18\~70 years old; expected survival period of\>12 weeks; multiple myeloma was diagnosed by physical examination, pathological examination, laboratory examination and imaging; patients with refractory multiple myeloma; patients with multiple myeloma recurrence; alt and ast \ 50%; the patient has no serious heart, liver, kidney and other diseases; recurrence or no disease remission after hematopoietic stem cell transplantation or cellular immunotherapy; is not suitable for stem cell transplantation conditions or to abandon transplantation due to conditional restrictions; blood can be obtained intravenously, without other contraindications to leukapheresis; understand and voluntarily sign a written informed consent form. exclusion criteria: women who are pregnant or breastfeeding, or who have a pregnancy plan within six months; infectious diseases (such as hiv, active tuberculosis, etc.); active hepatitis b or hepatitis c infection; feasibility assessment screening demonstrated \<10% transfection of targeted lymphocytes or underamplification under cd3 / cd28 costimulation (\<5-fold); abnormal vital signs, and unable to cooperate with the examination; have mental or mental illness who cannot cooperate with the treatment and efficacy evaluation; highly allergic constitution or have a history of severe allergies, especially allergic to il-2; subjects with a systemic infection or a severe local infection requiring anti-infective treatment; subjects with severe autoimmune disease; the doctor believes there were other reasons for inclusion

Keywords: multiple myeloma bcma fcrl5
role of laparoscopy in management of non-palpable undescended testis : assuit university experience

Conditions: Undescended Testes

Summary: 1. to evaluate the role of laparoscopy in diagnosis \& treatment of non- palpable undescended testis 2. to compare between different laparoscopic techniques 3. to introduce new laparoscopic technique in assuit university " shehata technique "

cryptorchidism or undescended testis (udt) is one of the most common genital anomalies in childhood. its incidence is 3-5 % in full term newborn, and affect more than one third of premature newborn. the incidence decrease to 1 % at age of 3months. about 20% of udt are impalpable, and about 50% of these impalpable testes are either vanished or atrophic (1-3). many diagnostic methods have been used for the evaluation and management of the undescended testis, including imaging studies and multiple surgical procedures. surgical management of udt is performed to preserve testicular function (spermatogenesis) and to prevent the potential complications of undescended testis(1). regarding the optimal age of orchiopexy many recent findings suggest that early intervention (6 -12 months of age) is most beneficial. other findings suggest that there is high rate of spontaneous descent during the first 3 months of life, so observation of undescended testis is advocated till 3 months of age, if the testis remains non-palpable at 3 months of age, it is unlikely to become palpable by waiting another 3 months. therefore, diagnostic laparoscopy and orchidopexy could be performed from 3 months of age(2). for intraabdominal cryptorchidism, laparoscopic surgery has been accepted by most surgeons as the preferred technique for diagnosis \& treatment (4). laparoscopic findings in non-palpable testis include ; absent testis either ; agenesis ( absence of spermatic vessels and vas deferens ) or vanishing testis ( blind ending of spermatic vessels or vas ) , canalicular testis ; penetration of vas and spermatic vessels into the internal inguinal ring with or without directly seeing the testis , abdominal testis localized between the inferior renal pole and the ipsilateral internal inguinal ring. can be low (\ 2cm) from internal inguinal ring , peeping ; primarily in intra-abdominal position. the testis introduces itself into the inguinal canal due to the intra-abdominal pressure augmentation during the laparoscopic procedure.(5) several techniques have been described for treatment of intra-abdominal testis including microsurgical auto-transplantation, primary laparoscopic orchiopexy (vilo), one- and two-stage laparoscopic fowler-stephens procedures, and staged laparoscopic traction orchiopexy (shehata technique

Eligibility criteria:
inclusion criteria: * any patient admitted to pediatric unit in assuit university hospital with non palpable testis ( npt )below age of 6 years exclusion criteria: * patients with npt above age of 6 years * patients with atrophic or vanishing testis * patients with previous failed laparoscopic orchiopexy
preventing postpartum relapse to smoking using yoga and cognitive behavioral therapy: a randomized pilot study

Conditions: Smoking Cessation

Summary: the purpose of this study is to develop strategies to maintain smoking abstinence initiated in pregnancy and prevent relapse in the postpartum period.

many women quit smoking during pregnancy, but postpartum relapse rates are high, approximately, 50-80% (van't hof, et al). the majority of women who quit smoking during pregnancy resume smoking within the first 3 months postpartum (mcbride, et al). the environmental risks of tobacco smoke on the newborn child can lead to acute respiratory infections, bronchitis, pneumonia, and sids. several studies have tried to identify reasons for the high rates of relapse. postpartum relapse has been attributed to decreased self-efficacy, the lack of effective coping strategies to resist temptation to smoke, and weight concerns (mcbride, et al). addictive behaviors such as smoking are learned behavioral means of coping. by learning new rules for dealing with problems, a behavior can be modified or unlearned. physical exercise, when combined with cognitive behavioral therapy (cbt) as a smoking cessation treatment, is useful in the maintenance of smoking cessation in women. yoga, as a form of exercise, has been shown to promote the desire to stop smoking and enhance subjective well-being and mood. though untested in postpartum relapse prevention, yoga practice, when coupled with cbt, may address both mood and physiologic postpartum sensations that may be associated with the prevention of smoking relapse. women are more apt to decrease or even stop smoking during pregnancy, and if successful in sustaining cessation, are likely to live longer. this randomized exploratory pilot study will use a controlled parallel group design using smoking cessation yoga intervention and cognitive behavioral therapy. the study will include a total of 30 participants aged 18-45 years. smoking status will be identified by self-report and carbon monoxide testing at enrollment. at randomization and following time points, smoking status will be identified by self-report and confirmed by carbon monoxide testing.

Eligibility criteria:
inclusion criteria: * must have the ability to read, write, and understand english. * must have quit smoking during their current pregnancy. * must possess the desire to remain smoke-free after delivery. * obtain permission from obstetrician to participate in yoga. * must be reachable by telephone. * if subject becomes pregnant again while in the study, she can still participate with written permission from her primary care physician. exclusion criteria: * untreated hypertension. * a history of: glaucoma, major depression, alcohol abuse or substance disorder, anorexia nervosa, or head trauma. * recent abdominal surgery (such as caesarean section).

Keywords: smoking abstinence
study comparing g-csf mobilized peripheral blood and g-csf stimulated bone marrow in patients undergoing matched sibling transplantation

Conditions: Transplantation for Hematologic Malignancies

Summary: this is a randomized multicentre study comparing gcsf mobilized peripheral blood and gcsf stimulated bone marrow in patients undergoing matched sibling transplantation for haematologic malignancies.


Eligibility criteria:
inclusion criteria: * recipient must 1. be between the ages of 16 and 65 years old 2. have one of the following hematologic malignancies: * acute myeloid leukemia (de novo, secondary or therapy related) in untreated 1st relapse or in remission or with evidence of molecular relapse but blasts less than 5% * chronic myeloid leukemia in chronic or accelerated phase (de novo or therapy related) * myelodysplasia (de novo or therapy related) * other hematologic malignancy (de novo or therapy related) including but not limited to: all (cr 1, cr2 or cr3), cll, non-hodgkin's lymphoma, hodgkin's lymphoma 3. must be receiving a myeloablative conditioning regimen of busulfan and cyclophosphamide or tbi and cyclophosphamide or other myeloablative regimen approved by the clinical study chair. (regimens containing atg are not allowed.) 4. have an hla-identical sibling donor 5. meet the transplant centre's criteria for myeloablative allogeneic transplantation\* 6. have an ecog performance status of 0, 1 or 2 7. have given signed informed consent donor must 1. be 18 years of age or older. (upper age limit is at the discretion of the transplant physician at the collection centre.) 2. be able to undergo general anesthesia and bm harvest or peripheral blood collection as per assessment by a transplant physician. (if an anesthetist assesses a donor after randomization and determines the donor should not undergo general anesthesia, then the donor and recipient will be withdrawn from the study.) 3. be a sibling of the recipient 4. be a 6/6 hla match of the recipient. hla typing is by serologic or dna methodology for a and b and by dna methodology for a and b and by dna methodology for drb1 (intermediate resolution) 5. have given signed informed consent exclusion criteria recipient 1. the recipient is hiv antibody positive donor 1. the donor is unable to undergo general anesthesia, bone marrow harvest or peripheral blood collection 2. the donor is pregnant or breastfeeding at the time of progenitor cell collection 3. the donor has a history of malignant disease within the last 5 years or current malignancy other than non-melanomatous in situ skin carcinoma or cervical carcinoma in situ 4. the donor is hiv antibody positive 5. the donor has a known sensitivity to e. coli-derived products 6. the donor and recipient are identical twins